1 21 4

Shareholder Tools

Home Investor Relations

Investor Relations

  1. Chart
  2. Quote
Stock price graph
+ 2.06
Day High:
Day Low:
4:00 PM ET on Jul 23, 2014

Delayed at least 20 minutes.
Provided by eSignal.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. MacroGenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. The combination of MacroGenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.

Corporate Fact Sheet

Corporate Fact Sheet

PDF  Corporate Fact Sheet

View all »   RSSRecent Releases

Jun 19, 2014
MacroGenics Initiates Phase 1 Study of MGD006 for the Treatment of Acute Myeloid Leukemia

May 27, 2014
MacroGenics and Takeda Enter Strategic Alliance to Develop DART for Treatment of Autoimmune Disorders